UBS AM
ALLO icon

UBS AM’s Allogene Therapeutics ALLO Stock Holding History

UBS AM’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-270,559
Closed -$576K – 2641
2024
Q4 		$576K Buy
270,559
+41,753
+18% +$103K ﹤0.01% 2531
2024
Q3 		$641K Sell
228,806
-37,978
-14% -$101K ﹤0.01% 2578
2024
Q2 		$622K Buy
266,784
+96,497
+57% +$285K ﹤0.01% 2566
2024
Q1 		$761K Buy
170,287
+13,578
+9% +$56.7K ﹤0.01% 2148
2023
Q4 		$503K Hold
156,709
– – ﹤0.01% 2318
2023
Q3 		$497K Sell
156,709
-376,527
-71% -$1.65M ﹤0.01% 2305
2023
Q2 		$2.63M Hold
533,236
– – ﹤0.01% 1526
2023
Q1 		$2.63M Buy
+533,236
New +$3.42M ﹤0.01% 1526
2022
Q4 		– Sell
-506,137
Closed -$5.47M – 2546
2022
Q3 		$5.47M Buy
506,137
+79,855
+19% +$1.09M ﹤0.01% 1167
2022
Q2 		$4.86M Buy
426,282
+23,425
+6% +$208K ﹤0.01% 1223
2022
Q1 		$3.67M Buy
402,857
+12,895
+3% +$134K ﹤0.01% 1488
2021
Q4 		$5.82M Buy
389,962
+2,021
+0.5% +$35.7K ﹤0.01% 1350
2021
Q3 		$9.97M Sell
387,941
-10,239
-3% -$243K ﹤0.01% 1099
2021
Q2 		$10.4M Buy
398,180
+172,689
+77% +$4.92M ﹤0.01% 1110
2021
Q1 		$7.91M Sell
225,491
-38,814
-15% -$1.31M ﹤0.01% 1160
2020
Q4 		$6.67M Buy
264,305
+3,961
+2% +$129K ﹤0.01% 1184
2020
Q3 		$9.82M Buy
260,344
+13,933
+6% +$525K 0.01% 948
2020
Q2 		$10.6M Buy
246,411
+63,727
+35% +$2.3M 0.01% 889
2020
Q1 		$3.55M Sell
182,684
-21,628
-11% -$515K ﹤0.01% 1190
2019
Q4 		$5.31M Buy
204,312
+9,226
+5% +$254K ﹤0.01% 1165
2019
Q3 		$5.32M Sell
195,086
-5,181
-3% -$148K ﹤0.01% 1183
2019
Q2 		$5.38M Buy
200,267
+2,142
+1% +$59.7K ﹤0.01% 1173
2019
Q1 		$5.73M Buy
198,125
+102,303
+107% +$2.97M ﹤0.01% 1102
2018
Q4 		$2.58M Buy
+95,822
New +$2.55M ﹤0.01% 1323

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM's ALLO Position: Q1 2025 in Review

UBS AM sold out of Allogene Therapeutics (ALLO) in Q1 2025, closing a stake of 270,559 shares — an estimated $576K sold.

UBS AM first reported a position in ALLO in Q4 2018 and held it in 24 quarters. The position peaked at $10.6M in Q2 2020. 170 funds tracked by Wall St. Rank hold ALLO as of Q1 2025.

  • UBS AM reported no remaining Allogene Therapeutics position as of Q1 2025 after selling out during the quarter.
  • UBS AM sold 270,559 Allogene Therapeutics shares in Q1 2025, an estimated $576K.
  • UBS AM first reported a position in Allogene Therapeutics in Q4 2018 and held it in 24 quarters.
  • UBS AM's Allogene Therapeutics position peaked at $10.6M in Q2 2020.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2025.

Based on UBS AM's 13F filing for Q1 2025, filed 19 May 2025.